JP2016505138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505138A5 JP2016505138A5 JP2015551784A JP2015551784A JP2016505138A5 JP 2016505138 A5 JP2016505138 A5 JP 2016505138A5 JP 2015551784 A JP2015551784 A JP 2015551784A JP 2015551784 A JP2015551784 A JP 2015551784A JP 2016505138 A5 JP2016505138 A5 JP 2016505138A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- target
- activatable antibody
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- -1 chromophore Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749220P | 2013-01-04 | 2013-01-04 | |
| US201361749212P | 2013-01-04 | 2013-01-04 | |
| US61/749,220 | 2013-01-04 | ||
| US61/749,212 | 2013-01-04 | ||
| US201361749529P | 2013-01-07 | 2013-01-07 | |
| US201361749486P | 2013-01-07 | 2013-01-07 | |
| US61/749,529 | 2013-01-07 | ||
| US61/749,486 | 2013-01-07 | ||
| US201361755810P | 2013-01-23 | 2013-01-23 | |
| US61/755,810 | 2013-01-23 | ||
| US201361763237P | 2013-02-11 | 2013-02-11 | |
| US61/763,237 | 2013-02-11 | ||
| US201361830940P | 2013-06-04 | 2013-06-04 | |
| US61/830,940 | 2013-06-04 | ||
| US201361897659P | 2013-10-30 | 2013-10-30 | |
| US61/897,659 | 2013-10-30 | ||
| PCT/US2014/010216 WO2014107599A2 (en) | 2013-01-04 | 2014-01-03 | Compositions and methods for detecting protease activity in biological systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019190445A Division JP7001652B2 (ja) | 2013-01-04 | 2019-10-17 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505138A JP2016505138A (ja) | 2016-02-18 |
| JP2016505138A5 true JP2016505138A5 (enExample) | 2017-02-09 |
| JP6605957B2 JP6605957B2 (ja) | 2019-11-13 |
Family
ID=51062553
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551784A Active JP6605957B2 (ja) | 2013-01-04 | 2014-01-03 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| JP2019190445A Active JP7001652B2 (ja) | 2013-01-04 | 2019-10-17 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| JP2021209234A Active JP7223832B2 (ja) | 2013-01-04 | 2021-12-23 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019190445A Active JP7001652B2 (ja) | 2013-01-04 | 2019-10-17 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| JP2021209234A Active JP7223832B2 (ja) | 2013-01-04 | 2021-12-23 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10261083B2 (enExample) |
| EP (1) | EP2941643A4 (enExample) |
| JP (3) | JP6605957B2 (enExample) |
| CN (2) | CN105008918A (enExample) |
| AU (2) | AU2014204015A1 (enExample) |
| CA (1) | CA2896282C (enExample) |
| HK (1) | HK1210831A1 (enExample) |
| RU (1) | RU2015132436A (enExample) |
| WO (1) | WO2014107599A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3026701C (en) | 2009-03-02 | 2023-04-18 | Massachusetts Institute Of Technology | Methods and products for in vivo enzyme profiling |
| WO2012125808A1 (en) | 2011-03-15 | 2012-09-20 | Massachusetts Institute Of Technology | Multiplexed detection with isotope-coded reporters |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| AU2013278075B2 (en) | 2012-06-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof |
| EP2941643A4 (en) | 2013-01-04 | 2016-09-28 | Cytomx Therapeutics Inc | Compositions and methods for detecting proteinase activity in biological systems |
| CA2913732A1 (en) | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| WO2014197840A1 (en) | 2013-06-07 | 2014-12-11 | Massachusetts Institute Of Technology | Affinity-based detection of ligand-encoded synthetic biomarkers |
| EP3024851B1 (en) * | 2013-07-25 | 2018-05-09 | CytomX Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| WO2015048329A2 (en) * | 2013-09-25 | 2015-04-02 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| IL270562B (en) | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Matriptase and u-plasminogen activator polypeptide substrates and other cleanable moieties, compositions comprising same and uses thereof |
| US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
| US20170233824A1 (en) * | 2014-08-18 | 2017-08-17 | Adrastia Biotech Corporation | Systems and methods of detecting solid tumor cancer |
| ES2789351T3 (es) | 2015-01-13 | 2020-10-26 | Hope City | Máscaras de enlace peptídico de proteínas de unión a CTLA4 |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| ES2796698T3 (es) | 2015-05-04 | 2020-11-30 | Cytomx Therapeutics Inc | Anticuerpos anti-CD166 activables y procedimientos de uso de los mismos |
| EP3736290A1 (en) | 2015-05-29 | 2020-11-11 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| CN107849145B (zh) | 2015-06-16 | 2021-10-26 | 基因泰克公司 | 抗cd3抗体及其使用方法 |
| DK3313874T3 (da) * | 2015-06-26 | 2021-05-03 | Univ Southern California | Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| PL3377103T5 (pl) | 2015-11-19 | 2025-07-07 | Revitope Limited | Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek |
| AR107469A1 (es) | 2016-01-27 | 2018-05-02 | Oncorus Inc | Vectores virales oncolíticos y sus usos |
| EP3213768A1 (en) | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer |
| EP3440013A4 (en) | 2016-04-08 | 2021-03-17 | Massachusetts Institute of Technology | METHODS FOR SPECIFICALLY PROFILING PROTEASE ACTIVITY AT LYMPHATIC GANGLIONS |
| CA3022928A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| MX2019006340A (es) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. |
| KR20190089034A (ko) | 2016-12-09 | 2019-07-29 | 시애틀 지네틱스, 인크. | 코일드 코일에 의해 차폐된 이가 항체 |
| EP3607085A1 (en) | 2017-04-07 | 2020-02-12 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| WO2019014586A1 (en) | 2017-07-14 | 2019-01-17 | Cytomx Therapeutics, Inc. | ANTI-CD166 ANTIBODIES AND USES THEREOF |
| CA3070299A1 (en) * | 2017-07-26 | 2019-01-31 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
| MX2020005463A (es) | 2017-12-01 | 2020-09-07 | Seattle Genetics Inc | Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer. |
| CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
| WO2019173332A1 (en) | 2018-03-05 | 2019-09-12 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| IL322964A (en) | 2018-05-14 | 2025-10-01 | Werewolf Therapeutics Inc | Activatable interleukin 12 polypeptides and methods of using them |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| US20210322508A1 (en) * | 2018-08-13 | 2021-10-21 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| WO2020068920A2 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス，インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| CA3122773A1 (en) * | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
| US20220226514A1 (en) * | 2019-05-17 | 2022-07-21 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
| TW202112354A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
| KR20220101147A (ko) | 2019-11-14 | 2022-07-19 | 웨어울프 세라퓨틱스, 인크. | 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법 |
| US11845799B2 (en) | 2019-12-13 | 2023-12-19 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| US12428470B2 (en) | 2020-04-09 | 2025-09-30 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CN111830254B (zh) * | 2020-07-29 | 2022-07-26 | 武汉生之源生物科技股份有限公司 | 一种基质金属蛋白酶-3测定试剂盒及其制备方法 |
| CN116973566A (zh) * | 2021-02-03 | 2023-10-31 | 广东菲鹏生物有限公司 | 一种鉴别结合突变型抗原的抗体的方法及试剂 |
| US20240352080A1 (en) | 2021-07-14 | 2024-10-24 | Seagen Inc. | Antibody Masking Domains |
| CN117813378A (zh) * | 2021-07-26 | 2024-04-02 | 乔治亚技术研究公司 | 用于通过免疫细胞展示进行体内蛋白酶谱分析的组合物和方法 |
| WO2023034825A1 (en) * | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| US20240376200A1 (en) | 2021-09-24 | 2024-11-14 | Seagen Inc. | Improved Antibody Masking Domains |
| US20250172557A1 (en) * | 2022-03-01 | 2025-05-29 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb ligands and blocking antibodies |
| IL316049A (en) | 2022-04-13 | 2024-11-01 | Genentech Inc | Musuntuzumab pharmaceutical preparations and methods of use |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| ES2368387T5 (es) | 2000-10-09 | 2019-03-07 | Cytomx Therapeutics Inc | Anticuerpos terapéuticos y que inducen tolerancia |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
| EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF |
| US20090220529A1 (en) | 2006-03-10 | 2009-09-03 | Diatos, S.A. | Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker |
| AU2007336243B2 (en) * | 2006-12-19 | 2012-07-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| JP2012511033A (ja) * | 2008-12-08 | 2012-05-17 | テゴファーム コーポレーション | 多価化合物の可逆阻害用マスキングリガンド |
| US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
| CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
| CA2871458C (en) | 2012-04-27 | 2020-06-23 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| AU2013278075B2 (en) * | 2012-06-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof |
| EP2941643A4 (en) | 2013-01-04 | 2016-09-28 | Cytomx Therapeutics Inc | Compositions and methods for detecting proteinase activity in biological systems |
-
2014
- 2014-01-03 EP EP14735246.2A patent/EP2941643A4/en active Pending
- 2014-01-03 JP JP2015551784A patent/JP6605957B2/ja active Active
- 2014-01-03 AU AU2014204015A patent/AU2014204015A1/en not_active Abandoned
- 2014-01-03 HK HK15111420.0A patent/HK1210831A1/xx unknown
- 2014-01-03 CN CN201480011969.7A patent/CN105008918A/zh active Pending
- 2014-01-03 CA CA2896282A patent/CA2896282C/en active Active
- 2014-01-03 US US14/147,324 patent/US10261083B2/en active Active
- 2014-01-03 CN CN202010717082.7A patent/CN112162094A/zh active Pending
- 2014-01-03 RU RU2015132436A patent/RU2015132436A/ru unknown
- 2014-01-03 WO PCT/US2014/010216 patent/WO2014107599A2/en not_active Ceased
-
2018
- 2018-10-18 AU AU2018250437A patent/AU2018250437B2/en active Active
-
2019
- 2019-02-15 US US16/277,497 patent/US11035859B2/en active Active
- 2019-10-17 JP JP2019190445A patent/JP7001652B2/ja active Active
-
2021
- 2021-04-30 US US17/246,167 patent/US11867695B2/en active Active
- 2021-12-23 JP JP2021209234A patent/JP7223832B2/ja active Active
-
2023
- 2023-11-09 US US18/506,072 patent/US20240337658A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505138A5 (enExample) | ||
| RU2015132436A (ru) | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления | |
| Guerrero et al. | Mechanistic peptidomics: factors that dictate specificity in the formation of endogenous peptides in human milk | |
| US9772328B2 (en) | Bimolecular protease-based biosensor | |
| JP2016538240A5 (enExample) | ||
| CN106796222B (zh) | 针对tsh受体的自身抗体的检测 | |
| Hoshijima et al. | Roles of heterotypic CCN2/CTGF–CCN3/NOV and homotypic CCN2–CCN2 interactions in expression of the differentiated phenotype of chondrocytes | |
| JP2017533181A5 (enExample) | ||
| Wang et al. | A fluorogenic peptide probe developed by in vitro selection using tRNA carrying a fluorogenic amino acid | |
| CN104769433A (zh) | 诊断或监测肾功能或者诊断肾功能异常的方法 | |
| Wang et al. | Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry | |
| SE0000675D0 (sv) | Monoclonal antibodies | |
| CN106568940A (zh) | 一种体外定量测定vWF‑CP酶活性的底物、方法及试剂盒 | |
| JP6624755B2 (ja) | プロテインタグ、タグ化タンパク質及びタンパク質精製方法 | |
| DE60219645D1 (de) | Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft | |
| Leung et al. | Osteopontin fragments with intact thrombin-sensitive site circulate in cervical cancer patients | |
| Mukherjee et al. | One-pot synthesis of heterodimeric agonists that activate the canonical Wnt signaling pathway | |
| WO2005103713A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| FR3001805A1 (fr) | Procede de detection d'un cancer colorectal | |
| JP2017037014A5 (enExample) | ||
| RU2005115973A (ru) | Растворимые субстраты на основе notch для гамма-секретазы, а также способы и композиции для их применения | |
| EP3362473B1 (en) | Use of a fibrinogen capture agent to detect a ciz1 b-variant | |
| US10502741B2 (en) | Means and methods for detecting activated MALT1 | |
| Jägerbrink et al. | Proinsulin C-peptide interaction with protein tyrosine phosphatase 1B demonstrated with a labeling reaction | |
| CN112462074B (zh) | 一种cd277三种亚型蛋白的鉴定方法及检测试剂盒 |